View Filing Data

Sales of generic pharmaceutical products [Member]

$ 46,483

$ 36,628

Sales of branded pharmaceutical products [Member]

23,227

26,572

Sales of contract manufactured products [Member]

16,595

8,039

Royalties on sales of pharmaceutical products [Member]

945

1,793

5,382

Other [Member]

Reserve for excess/obsolete inventories

^[1]

$ 334

$ 224

[1]	Primarily includes laboratory services and royalties on sales of contract manufactured products

REVENUE RECOGNITION AND RELATED ALLOWANCES (Details 1) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2018	Mar. 31, 2017
Valuation and Qualifying Accounts Disclosure [Line Items]
Beginning balance	$ 34,686
Ending balance	30,786
Chargebacks [Member]
Valuation and Qualifying Accounts Disclosure [Line Items]
Beginning balance	28,230	$ 26,785
Accruals/Adjustments	38,217	38,191
Credits Taken Against Reserve	(42,696)	(40,442)
Ending balance	23,751	24,534
Government Rebates [Member]
Valuation and Qualifying Accounts Disclosure [Line Items]
Beginning balance	7,930	5,891
Accruals/Adjustments	1,795	1,821
Credits Taken Against Reserve	(3,254)	(3,057)
Ending balance	6,471	4,655
Returns [Member]
Valuation and Qualifying Accounts Disclosure [Line Items]
Beginning balance	8,274	5,756
Accruals/Adjustments	3,644	1,855
Credits Taken Against Reserve	(2,898)	(1,835)
Ending balance	9,020	5,776
Administrative Fees And Other Rebates [Member]
Valuation and Qualifying Accounts Disclosure [Line Items]
Beginning balance	5,226	3,550
Accruals/Adjustments	7,584	5,030
Credits Taken Against Reserve	(6,792)	(4,755)
Ending balance	6,018	3,825
Prompt Payment Discounts [Member]
Valuation and Qualifying Accounts Disclosure [Line Items]
Beginning balance	1,834	1,554
Accruals/Adjustments	1,890	1,662
Credits Taken Against Reserve	(2,142)	(1,737)
Ending balance	$ 1,582	$ 1,479

REVENUE RECOGNITION AND RELATED ALLOWANCES (Details Textual) - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2018	Mar. 31, 2017
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Period	5 months
Sales of contract manufactured products [Member]
Revenue, Remaining Performance Obligation	$ 2.3
Performance Obligation From Prior Period [Member]
Revenue, Net	$ 3.3
Customer One [Member] \| Net Revenues [Member]
Concentration Risk, Percentage	34.00%	31.00%
Customer Two [Member] \| Net Revenues [Member]
Concentration Risk, Percentage	25.00%	25.00%
Customer Three [Member] \| Net Revenues [Member]
Concentration Risk, Percentage	20.00%	20.00%
Customer One Two And Three [Member] \| Net Accounts Receivable [Member]
Concentration Risk, Percentage	79.00%

INDEBTEDNESS (Details) - USD ($) $ in Thousands	Mar. 31, 2018	Dec. 31, 2017
Principal amount	$ 143,750	$ 143,750
Unamortized debt discount	(12,187)	(13,924)
Deferred financing costs	(1,407)	(1,618)
Net carrying value	$ 130,156	$ 128,208

INDEBTEDNESS (Details 1) - USD ($) $ in Thousands	Mar. 31, 2018	Dec. 31, 2017
Borrowing on secured term loan	$ 143,750	$ 143,750
Current component of long-term borrowing, net of unamortized deferred financing costs	3,805	3,353
Long-term borrowing, net of unamortized deferred financing costs and current borrowing component	68,569	69,946
Long Term Debt Current [Member]
Borrowing on secured term loan	4,219	3,750
Unamortized deferred financing costs	(414)	(397)
Current component of long-term borrowing, net of unamortized deferred financing costs	3,805	3,353
Long Term Debt Noncurrent [Member]
Borrowing on secured term loan	69,844	71,250
Unamortized deferred financing costs	(1,275)	(1,304)
Long-term borrowing, net of unamortized deferred financing costs and current borrowing component	$ 68,569	$ 69,946

INDEBTEDNESS (Details 2) - USD ($) $ in Thousands	3 Months Ended
INDEBTEDNESS (Details 2) - USD ($) $ in Thousands	Mar. 31, 2018	Mar. 31, 2017
Contractual coupon	$ 1,724	$ 1,078
Amortization of debt discount	1,737	1,647
Amortization of finance fees	370	211
Capitalized interest	(192)	(90)
Interest Expense, Debt	$ 3,639	$ 2,846

INDEBTEDNESS (Details Textual) - USD ($) $ / shares in Units, $ in Thousands	12 Months Ended
	Dec. 31, 2017	Mar. 31, 2018	Dec. 31, 2014
Long-term Debt, Gross	$ 143,750	$ 143,750
Long-term Debt, Percentage Bearing Fixed Interest, Percentage Rate	3.00%
Debt Instrument, Unamortized Discount	$ 13,924	$ 12,187
Long-term Debt [Member]
Debt Instrument, Interest Rate, Effective Percentage		6.70%
Senior Secured Credit Facility [Member] \| Citizens Bank, N.A. [Member]
Debt Instrument, Term	5 years
Debt Issuance Costs, Gross		$ 2,900
Prepaid Expenses and Other Current Assets [Member] \| Revolving Credit Facility [Member]
Debt Issuance Costs, Current, Net		200
Other Longterm Assets [Member] \| Revolving Credit Facility [Member]
Debt Issuance Costs, Gross		1,100
Other Noncurrent Assets [Member] \| Revolving Credit Facility [Member]
Line of Credit Facility, Maximum Borrowing Capacity	$ 50,000
Debt Issuance Costs, Noncurrent, Net		800
Convertible Senior Notes [Member]
Long-term Debt, Gross			$ 143,800
Long-term Debt, Percentage Bearing Fixed Interest, Percentage Rate			3.00%
Debt Instrument, Unamortized Discount			$ 33,600
Class of Warrant or Right, Exercise Price of Warrants or Rights			$ 96.21
Debt Instrument, Convertible, Conversion Price			$ 69.48
Convertible Senior Notes [Member] \| Accrued Liabilities [Member]
Interest Payable, Current	400	1,400
Term Loan [Member] \| Citizens Bank, N.A. [Member]
Debt Instrument Periodic Payment To Be Paid In Installments		4,200
Debt Instrument, Face Amount	$ 75,000	74,100
Debt Issuance Costs, Gross		1,800
Current Term Loan [Member] \| Citizens Bank, N.A. [Member]
Debt Instrument, Face Amount		$ 4,200

EARNINGS PER SHARE (Details) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands	3 Months Ended
	Mar. 31, 2018	Mar. 31, 2017
Net income, Basic	$ 2,250	$ 1,152
Net income, Diluted	2,250	1,152
Net income allocated to common shares, Basic	2,237	1,141
Net income allocated to common shares, Diluted	$ 2,237	$ 1,141
Basic Weighted-Average Shares Outstanding, Basic	11,589	11,527
Dilutive effect of stock options and ESPP, Diluted	117	126
Diluted Weighted-Average Shares Outstanding, Diluted	11,706	11,653
Earnings Per Share, Basic	$ 0.19	$ 0.1
Earnings Per Share, Diluted	$ 0.19	$ 0.1
Restricted Stock [Member]
Net income allocated to restricted stock, Basic	$ (13)	$ (11)
Net income allocated to restricted stock, Diluted	$ (13)	$ (11)

EARNINGS PER SHARE (Details Textual) - shares shares in Millions	3 Months Ended
	Mar. 31, 2018	Mar. 31, 2017
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	4.6	4.6

INVENTORIES (Details) - USD ($)
$ in Thousands

Mar. 31, 2018

Dec. 31, 2017

Inventories

Raw materials

$ 23,518

$ 22,139

Packaging materials

1,623

1,527

Work-in-progress

746

510

Finished goods

^[1]

8,914

13,901

Inventory, Gross, Total

34,801

38,077

(507)

(350)

Inventories, net

$ 34,294

$ 37,727

[1]	Includes finished goods acquired in asset purchases (Note 11).

INVENTORIES (Details Textual) - USD ($) $ in Thousands	3 Months Ended
INVENTORIES (Details Textual) - USD ($) $ in Thousands	Mar. 31, 2018	Mar. 31, 2017	Dec. 31, 2017
Accounts Payable, Current	$ 4,886		$ 3,630
Two Suppliers - Three Months Ended March 31, 2018 [Member]
Concentration Risk, Percentage	29.00%
Accounts Payable, Current	$ 2,100
Two Suppliers - Three Months Ended March 31, 2017 [Member]
Concentration Risk, Percentage		33.00%

PROPERTY, PLANT, AND EQUIPMENT (Details) - USD ($) $ in Thousands	Mar. 31, 2018	Dec. 31, 2017
Property, Plant and Equipment, Gross, Total	$ 28,540	$ 26,992
Less: accumulated depreciation	(6,658)	(6,589)
Property, Plant, and Equipment, net	21,882	20,403
Land [Member]
Property, Plant and Equipment, Gross, Total	160	160
Buildings [Member]
Property, Plant and Equipment, Gross, Total	3,835	3,835
Machinery, furniture and equipment [Member]
Property, Plant and Equipment, Gross, Total	12,766	12,334
Construction in progress [Member]
Property, Plant and Equipment, Gross, Total	$ 11,779	$ 10,663

PROPERTY, PLANT, AND EQUIPMENT (Details Textual) - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2018	Mar. 31, 2017
Depreciation, Total	$ 0.3	$ 0.3
Interest Costs Capitalized	$ 0.2	$ 0.1

GOODWILL AND INTANGIBLE ASSETS (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2018	Dec. 31, 2017
GOODWILL AND INTANGIBLE ASSETS
Gross Carrying Amount	$ 284,716	$ 284,716
Accumulated Amortization	(62,799)	(54,926)
Acquired ANDA intangible assets
GOODWILL AND INTANGIBLE ASSETS
Gross Carrying Amount	42,076	42,076
Accumulated Amortization	$ (13,642)	(12,592)
Weighted Average Amortization Period	10 years
NDAs and product rights
GOODWILL AND INTANGIBLE ASSETS
Gross Carrying Amount	$ 230,974	230,974
Accumulated Amortization	$ (43,374)	(37,091)
Weighted Average Amortization Period	10 years
Marketing and distribution rights
GOODWILL AND INTANGIBLE ASSETS
Gross Carrying Amount	$ 11,042	11,042
Accumulated Amortization	$ (5,605)	(5,087)
Weighted Average Amortization Period	4 years 8 months 12 days
Non-compete agreement
GOODWILL AND INTANGIBLE ASSETS
Gross Carrying Amount	$ 624	624
Accumulated Amortization	$ (178)	$ (156)
Weighted Average Amortization Period	7 years

GOODWILL AND INTANGIBLE ASSETS (Details 1) $ in Thousands	Mar. 31, 2018 USD ($)
GOODWILL AND INTANGIBLE ASSETS
2018 (remainder of the year)	$ 23,619
2019	31,492
2020	31,010
2021	29,564
2022	26,099
2023 and thereafter	80,133
Total	$ 221,917

GOODWILL AND INTANGIBLE ASSETS (Details Textual) - USD ($) $ in Thousands	1 Months Ended		3 Months Ended
	Dec. 31, 2017	Feb. 28, 2017	Mar. 31, 2018	Mar. 31, 2017
GOODWILL AND INTANGIBLE ASSETS
Amortization of Intangible Assets			$ 7,900	$ 6,400
Payments to Acquire Intangible Assets			0	$ 50,956
Goodwill	$ 1,838		1,838
Finite-Lived Intangible Assets, Gross	284,716		$ 284,716
Acquired Finite-lived Intangible Asset, Amortization Description			we are amortizing 80% of the value of the intangible assets over the first five years of useful lives of the assets and amortizing the remaining 20% of the value of the intangible assets over the second five years of useful lives of the assets.
Inderal XL [Member]
GOODWILL AND INTANGIBLE ASSETS
Finite-Lived Intangible Asset, Useful Life		10 years
Finite-Lived Intangible Assets, Gross		$ 15,100
Acquisition Costs Capitalized		40
Asset Acquisition Purchase Price		$ 20,200
InnoPran XL [Member]
GOODWILL AND INTANGIBLE ASSETS
Finite-Lived Intangible Asset, Useful Life		10 years
Finite-Lived Intangible Assets, Gross		$ 19,000
Acquisition Costs Capitalized		100
Asset Acquisition Purchase Price		30,600
InnoPran XL [Member] \| Line of Credit [Member]
GOODWILL AND INTANGIBLE ASSETS
Payments to Acquire Intangible Assets		30,000
InnoPran XL [Member] \| Cash [Member]
GOODWILL AND INTANGIBLE ASSETS
Payments to Acquire Intangible Assets		$ 600
AstraZeneca AB and AstraZeneca UK Limited [Member] \| New Drug Applications [Member]
GOODWILL AND INTANGIBLE ASSETS
Payments to Acquire Intangible Assets	$ 46,500
Finite-Lived Intangible Asset, Useful Life	10 years
Finite-Lived Intangible Assets, Gross	$ 46,700
Acquisition Costs Capitalized	$ 200

STOCK-BASED COMPENSATION (Details) - USD ($) $ in Thousands	3 Months Ended
STOCK-BASED COMPENSATION (Details) - USD ($) $ in Thousands	Mar. 31, 2018	Mar. 31, 2017
Allocated Share-based Compensation Expense	$ 1,360	$ 1,371
Cost of Sales [Member] \| 2008 Plan [Member]
Allocated Share-based Compensation Expense	18	23
Research and Development Expense [Member] \| 2008 Plan [Member]
Allocated Share-based Compensation Expense	160	139
Selling, General and Administrative Expenses [Member] \| 2008 Plan [Member]
Allocated Share-based Compensation Expense	$ 1,182	$ 1,209

STOCK-BASED COMPENSATION (Details 1) - shares shares in Thousands	3 Months Ended
	Mar. 31, 2018	Mar. 31, 2017
Options [Member]
Option Shares
Outstanding at the beginning of the period (in shares)	767	578
Granted (in shares)	5	182
Options Exercised/RSAs Vested (in shares)	(79)	(1)
Forfeited (in shares)	(11)	(2)
Outstanding at the end of the period (in shares)	682	757
RSAs [Member]
Option Shares
Outstanding at the beginning of the period (in shares)	86	63
Granted (in shares)	0	50
Options Exercised/RSAs Vested (in shares)	(16)	(4)
Forfeited (in shares)	0	0
Outstanding at the end of the period (in shares)	70	109

STOCK-BASED COMPENSATION (Details Textual) - USD ($) $ in Thousands, shares in Millions	3 Months Ended
	Mar. 31, 2018	Mar. 31, 2017
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Allocated Share-based Compensation Expense	$ 1,360	$ 1,371
2008 Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant	0.8
Employee Stock Purchase Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized	0.2
Share-based Compensation Arrangement by Share-based Payment Award, Discount from Market Price, Purchase Date	15.00%
Employee Stock Purchase Plan [Member] \| Cost of Sales [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Allocated Share-based Compensation Expense	$ 2	1
Employee Stock Purchase Plan [Member] \| Research and Development Expense [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Allocated Share-based Compensation Expense	2
Employee Stock Purchase Plan [Member] \| Selling, General and Administrative Expenses [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Allocated Share-based Compensation Expense	$ 14	$ 14

INCOME TAXES (Details Textual) - USD ($) $ in Millions	3 Months Ended		12 Months Ended
INCOME TAXES (Details Textual) - USD ($) $ in Millions	Mar. 31, 2018	Mar. 31, 2017	Dec. 31, 2017
Effective Income Tax Rate Reconciliation, Percent	20.80%
Deferred Tax Assets, Valuation Allowance	$ 0.3
Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent	21.00%	31.20%	35.00%

COMMITMENTS AND CONTINGENCIES (Details Textual) - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2018	Mar. 31, 2017
COMMITMENTS AND CONTINGENCIES
Percentage Of Royalties On Net Sales Of Unapproved Products	less than 1%	less than 1%
Unapproved Products [Member]
COMMITMENTS AND CONTINGENCIES
Revenue, Net	$ 5.6	$ 6.2
Unapproved Products [Member] \| Contract Customer [Member]
COMMITMENTS AND CONTINGENCIES
Revenue, Net	$ 0.4	$ 0.6

FAIR VALUE DISCLOSURES (Details Textual) - USD ($)
$ in Thousands

1 Months Ended

3 Months Ended

Dec. 31, 2017

Feb. 28, 2017

Mar. 31, 2018

Mar. 31, 2017

Fair Value Inputs, Assets, Quantitative Information

15.00%

$ 0

$ 50,956

Long-term Debt, Total

130,200

Inventory, Finished Goods, Gross

$ 284,716

284,716

^[1]

$ 13,901

8,914

Inderal XL [Member]

Fair Value Inputs, Assets, Quantitative Information

10.00%

Finite-Lived Intangible Asset, Useful Life

$ 15,100

10 years

Acquisition Costs Capitalized

$ 40

Inventory, Finished Goods, Gross

5,000

Asset Acquisition Purchase Price

$ 20,200

InnoPran XL [Member]

Fair Value Inputs, Assets, Quantitative Information

10.00%

Finite-Lived Intangible Asset, Useful Life

$ 19,000

10 years

Acquisition Costs Capitalized

$ 100

Inventory, Finished Goods, Gross

11,600

Asset Acquisition Purchase Price

30,600

InnoPran XL [Member] | Cash [Member]

Fair Value Inputs, Assets, Quantitative Information

InnoPran XL [Member] | Line of Credit [Member]

600

Fair Value Inputs, Assets, Quantitative Information

Fair Value, Inputs, Level 1 [Member]

$ 30,000

Fair Value Inputs, Assets, Quantitative Information

Notes Payable, Fair Value Disclosure

$ 156,600

AstraZeneca AB and AstraZeneca UK Limited [Member] | New Drug Applications [Member]

Fair Value Inputs, Assets, Quantitative Information

10.00%

$ 46,500